These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 19411682

  • 21. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.
    Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, Antràs L, Smith M, Neary MP, Duh MS.
    Cancer; 2007 Mar 15; 109(6):1090-6. PubMed ID: 17311345
    [Abstract] [Full Text] [Related]

  • 22. Risk factors contributing to the development of hypocalcemia after zoledronic acid administration in patients with bone metastases of solid tumor.
    Hanamura M, Iwamoto T, Soga N, Sugimura Y, Okuda M.
    Biol Pharm Bull; 2010 Mar 15; 33(4):721-4. PubMed ID: 20410614
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Optimal management of metastatic bone disease.
    Major P.
    Eur J Oncol Nurs; 2007 Mar 15; 11 Suppl 2():S32-7. PubMed ID: 17804294
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Zoledronic acid in metastatic bone disease: an audit based discussion.
    Akbar RA, Gosh SK, Khalil S, ul Haq SM.
    J Ayub Med Coll Abbottabad; 2010 Mar 15; 22(3):5-7. PubMed ID: 22338405
    [Abstract] [Full Text] [Related]

  • 27. Severe symptomatic hypocalcemia in a patient with RDEB treated with intravenous zoledronic acid.
    Perman MJ, Lucky AW, Heubi JE, Azizkhan RG.
    Arch Dermatol; 2009 Jan 15; 145(1):95-6. PubMed ID: 19153360
    [No Abstract] [Full Text] [Related]

  • 28. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
    Kawada K, Minami H, Okabe K, Watanabe T, Inoue K, Sawamura M, Yagi Y, Sasaki T, Takashima S.
    Jpn J Clin Oncol; 2005 Jan 15; 35(1):28-33. PubMed ID: 15681601
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer.
    Hong SJ, Cho KS, Cho HY, Ahn H, Kim CS, Chung BH.
    Yonsei Med J; 2007 Dec 31; 48(6):1001-8. PubMed ID: 18159593
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years.
    Guarneri V, Donati S, Nicolini M, Giovannelli S, D'Amico R, Conte PF.
    Oncologist; 2005 Dec 31; 10(10):842-8. PubMed ID: 16314295
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
    Storto G, Klain M, Paone G, Liuzzi R, Molino L, Marinelli A, Soricelli A, Pace L, Salvatore M.
    Bone; 2006 Jul 31; 39(1):35-41. PubMed ID: 16434248
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases.
    Smith A, Kressley A, Saif MW.
    JOP; 2009 Mar 09; 10(2):212-4. PubMed ID: 19287122
    [No Abstract] [Full Text] [Related]

  • 38. Symptomatic hypocalcemia following intravenous administration of zoledronic acid in a breast cancer patient.
    Mishra A.
    J Postgrad Med; 2008 Mar 09; 54(3):237. PubMed ID: 18626181
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.
    Henley D, Kaye J, Walsh J, Cull G.
    Intern Med J; 2005 Dec 09; 35(12):726-8. PubMed ID: 16313549
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.